Conrad Chan Selected Research

Trastuzumab (Herceptin)

9/2023	[225Ac]Ac- and [111In]In-DOTA-trastuzumab theranostic pair: cellular dosimetry and cytotoxicity in vitro and tumour and normal tissue uptake in vivo in NRG mice with HER2-positive human breast cancer xenografts.
12/2022	Formulation of a kit under Good Manufacturing Practices (GMP) for preparing [111In]In-BnDTPA-trastuzumab-NLS injection: a theranostic agent for imaging and Meitner-Auger Electron (MAE) radioimmunotherapy of HER2-positive breast cancer.
10/2020	The pharmaceutical stability of trastuzumab after short-term storage at room temperature assessed by analytical techniques and tumour imaging by microSPECT/CT.
1/2020	Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [111In]In-Bn-DTPA-nimotuzumab in mice with triple-negative or trastuzumab-resistant human breast cancer xenografts that overexpress EGFR.
1/2018	Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with 89Zr-Labeled Trastuzumab-DM1: A Comparison with 89Zr-Labeled Trastuzumab.
1/2017	Development and preclinical studies of 64Cu-NOTA-pertuzumab F(ab')2 for imaging changes in tumor HER2 expression associated with response to trastuzumab by PET/CT.
3/2016	Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
6/2015	Trastuzumab Labeled to High Specific Activity with (111)In by Site-Specific Conjugation to a Metal-Chelating Polymer Exhibits Amplified Auger Electron-Mediated Cytotoxicity on HER2-Positive Breast Cancer Cells.
4/2015	Advancing novel molecular imaging agents from preclinical studies to first-in-humans phase I clinical trials in academia--a roadmap for overcoming perceived barriers.
2/2015	Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of (111)In-BzDTPA-pertuzumab.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Conrad Chan Research Topics

Disease

18	Breast Neoplasms (Breast Cancer) 09/2023 - 08/2007
16	Neoplasms (Cancer) 11/2022 - 12/2002
3	Brain Neoplasms (Brain Tumor) 09/2023 - 10/2011
2	Infertility (Sterility) 12/2022 - 01/2011
2	Triple Negative Breast Neoplasms 11/2022 - 01/2020
2	Body Weight (Weight, Body) 05/2020 - 01/2020
1	Carcinoma (Carcinomatosis) 11/2022
1	Pancreatic Neoplasms (Pancreatic Cancer) 05/2020
1	Leukemia 10/2016
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2016
1	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 10/2016
1	Glioma (Gliomas) 10/2011
1	Inflammation (Inflammations) 10/2011
1	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2011
1	Glioblastoma (Glioblastoma Multiforme) 10/2005

Drug/Important Bio-Agent (IBA)

15	Trastuzumab (Herceptin)FDA Link 09/2023 - 08/2007
7	Epidermal Growth Factor (EGF)IBA 01/2020 - 12/2002
6	Pentetic Acid (DTPA)FDA LinkGeneric 01/2020 - 10/2005
4	Immunoconjugates (Immunoconjugate)IBA 01/2019 - 03/2006
3	Proteins (Proteins, Gene)FDA Link 12/2022 - 10/2005
3	Saline SolutionIBA 05/2020 - 03/2016
3	Peptides (Polypeptides)IBA 01/2019 - 03/2006
3	pertuzumabIBA 01/2017 - 01/2015
3	Chelating AgentsIBA 06/2015 - 10/2005
2	Nuclear Localization Signals (Nuclear Localization Signal)IBA 12/2022 - 08/2013
2	RadiopharmaceuticalsIBA 12/2022 - 10/2005
2	GoldIBA 11/2022 - 11/2011
2	Panitumumab (Vectibix)FDA Link 05/2020 - 01/2019
2	ErbB Receptors (EGF Receptor)IBA 03/2016 - 11/2007
2	MetalsIBA 06/2015 - 10/2005
2	Immunoglobulin Fab FragmentsIBA 08/2011 - 01/2011
2	Monoclonal AntibodiesIBA 01/2011 - 08/2007
2	AcidsIBA 03/2010 - 11/2007
2	Immunoglobulin G (IgG)IBA 03/2006 - 12/2002
1	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 09/2023
1	Radioisotopes (Radionuclides)IBA 12/2022
1	EndotoxinsIBA 12/2022
1	Therapeutic UsesIBA 11/2022
1	neodymium pyrocatechin disulfonate (NPD)IBA 11/2022
1	AntibodiesIBA 11/2022
1	Gemcitabine FDA Link 05/2020
1	1,4,7- triazacyclononane- N,N',N''- triacetic acid (NOTA)IBA 05/2020
1	rucaparibIBA 05/2020
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 05/2020
1	CreatinineIBA 05/2020
1	nimotuzumabIBA 01/2020
1	His-His-His-His-His-His ((His)6)IBA 01/2019
1	Ado-Trastuzumab EmtansineIBA 01/2018
1	Interleukin-3 Receptors (Interleukin 3 Receptor)IBA 10/2016
1	PolymersIBA 06/2015
1	Dendrimers (Dendrons)IBA 08/2013
1	TurpentineIBA 10/2011
1	scyllitol (scyllo-inositol)IBA 10/2011
1	64Cu-DOTA-trastuzumabIBA 08/2011
1	64Cu-DOTA-rituximabIBA 08/2011
1	Tumor Viral Antigens (Large T Antigen)IBA 08/2007
1	EpitopesIBA 03/2006
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2005
1	apotransferrinIBA 10/2005
1	Transferrin (beta 2 Transferrin)IBA 10/2005

Therapy/Procedure

5	Radioimmunotherapy 12/2022 - 03/2016
3	Precision Medicine 09/2023 - 05/2020
1	Immunotherapy 11/2022
1	Brachytherapy 11/2022
1	Therapeutics 04/2015
1	Radiotherapy 02/2010